DIAGNOS Announces a One-Year Agreement in North Africa with a Major Pharmaceutical Company after Successful Pilot

BROSSARD, QUEBEC--(Marketwired - Oct. 24, 2017) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK)(OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a positive conclusion to a pilot project by signing a turnkey one-year screening contract in North Africa.